Regents of the University of Minnesota v. AGA Medical Corp.

660 F. Supp. 2d 1037, 2009 U.S. Dist. LEXIS 90289, 2009 WL 3164778
CourtDistrict Court, D. Minnesota
DecidedSeptember 29, 2009
DocketCase 07-CV-4732 (PJS/RLE)
StatusPublished
Cited by2 cases

This text of 660 F. Supp. 2d 1037 (Regents of the University of Minnesota v. AGA Medical Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Regents of the University of Minnesota v. AGA Medical Corp., 660 F. Supp. 2d 1037, 2009 U.S. Dist. LEXIS 90289, 2009 WL 3164778 (mnd 2009).

Opinion

MARKMAN ORDER

PATRICK J. SCHILTZ, District Judge.

This matter is before the Court for construction of certain terms found in the claims of U.S. Patent No. 6,077,281 (the '281 patent) and U.S. Patent No. 6,077,291 (the '291 patent) in accordance with Markman v. Westview Instruments, Inc., 517 U.S. 370, 390-91, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996). The parties prepared an amended joint claim-construction statement (“JCCS”), and each side submitted two briefs (opening and response) on claim-construction issues. The Court held a Markman hearing on April 17, 2009.

I. BACKGROUND

Plaintiff Regents of the University of Minnesota (“the University”) brings suit against defendant AGA Medical Corp. *1040 (“AGA”) for infringement of the '281 and '291 patents. Both patents cover medical devices for repairing heart defects. The University owns the patents, which are part of a family of four patents covering inventions made by Gladwin S. Das. The University prosecuted all four patents as Das’s assignee.

The Das patents descend from an application filed in 1992. The University abandoned the original application, but subsequent divisional applications resulted in four patents: U.S. Patent No. 5,334,217, issued in April 1994; U.S. Patent No. 5,578,045, issued in November 1996; and the '281 and '291 patents, both of which were issued on June 20, 2000. These four patents include different claims but generally share the same specification. 1

Further, during prosecution of both the '281 and '291 patents, the University agreed to file a terminal disclaimer with respect to each patent. JA 206; 2 JA 437. Terminal disclaimers are a means of overcoming a rejection based on “non-statutory double patenting,” a doctrine under which a continuation patent can be held to be obvious (and therefore invalid) in light of a related patent that issued earlier from the same application as the continuation patent. See Geneva Pharms., Inc. v. GlaxoSmithKline PLC, 349 F.3d 1373, 1377-78 (Fed.Cir.2003). By means of a terminal disclaimer, the patentee gives up (“disclaims”) any portion of the continuation patent’s term that exceeds the term of the related patent. Id.; 37 C.F.R. § 1.130; Manual of Pat. Exam. Proc. § 718.

A terminal disclaimer is, in essence, a concession by the patentee that two patents that resulted from the same application should be treated as a single patent, effective for a single patent term. Put differently, the claims of the continuation patent are treated as if they appeared in the first patent. In this case, as the result of terminal disclaimers, the '281 and '291 patents expire at the same time as U.S. Patent No. 5,334,217.

Roughly speaking, the Das patents cover a closure device for repairing a hole between two chambers of a human heart. The closure device is delivered through a catheter that is threaded through a vein or artery until the catheter’s far end reaches the chamber of the heart featuring the hole to be closed.

The closure device features two disks that are joined at the center. The disks, which are springy, are folded up and pushed through a catheter. The far end of the catheter is placed through the hole in the heart. The device is then pushed forward through the catheter until the first of the two disks comes out of the catheter on the far side of the hole and springs back into its disk-like shape. The catheter is then pulled back to the near side of the hole with the second half of the device (i.e., the second disk) still inside the catheter. The device is pushed forward again until the second disk springs out, this time on the near side of the hole. The area where *1041 the two disks are joined blocks the hole, and the disks stay in position for two reasons: (1) they are bigger than the hole, and (2) they are springy. The central portion of the disk eventually becomes solid in one of a number of ways, and at that point, the hole is closed.

This description is, of course, oversimplified. The devil is in the device’s details, which are precisely the focus of the parties’ claim-construction arguments. The Court addresses those arguments below as it construes the disputed terms of the '281 and '291 patents.

II. GENERAL PRINCIPLES

Courts, not juries, construe patent claims. Markman, 517 U.S. at 391, 116 S.Ct. 1384. Language in a particular claim must be construed in the context of both that individual claim and the entire patent, including the specification. Phillips v. AWH Corp., 415 F.3d 1303, 1313 (Fed.Cir.2005) (en banc). Indeed, the specification, read in light of the prosecution history, is the primary basis for construing patent claims. Id. at 1315. Generally, the prosecution history of each patent in a family of patents is relevant to construing the claims of all patents in that family. See, e.g., NTP, Inc. v. Research in Motion, Ltd., 418 F.3d 1282, 1293 (Fed.Cir.2005) (“Because [the] patents all derive from the same parent application and share many common terms, we must interpret the claims consistently across all asserted patents.”).

Courts may also rely on “extrinsic evidence” — anything other than the patent and its prosecution history — but that evidence is secondary to the intrinsic evidence. Phillips, 415 F.3d at 1317. In general, claim language means whatever it would have meant, ordinarily and customarily, to a person of ordinary skill in the art at the time the patent application was filed. Id. at 1312-13. In some cases, the ordinary and customary meaning of claim language to a person of ordinary skill in the art may be identical to the meaning that the language would have to a lay person who is not skilled in the art. Id. at 1314.

III. CLAIM CONSTRUCTION

The parties have not argued that someone of ordinary skill in the art would interpret any of the disputed language differently than would an educated lay person. Instead, the parties’ arguments have focused on the '281 and '291 patents themselves, the prosecution history, and definitions from both general-purpose and technical dictionaries. Further, AGA agreed at the Markman hearing that its arguments did not depend on the definition of a person of ordinary skill in the art. Hr’g. Tr. at 10-11 [Docket No. 108]. And the University generally asks the Court either not to construe the disputed terms at all, or to construe them according to their ordinary meaning. Am. JCCS Sched. B [Docket No. 64], The Court therefore construes the terms as would an ordinary educated layperson who had access to technical dictionaries.

A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Regents of University of Minnesota v. AGA Medical Corp.
835 F. Supp. 2d 711 (D. Minnesota, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
660 F. Supp. 2d 1037, 2009 U.S. Dist. LEXIS 90289, 2009 WL 3164778, Counsel Stack Legal Research, https://law.counselstack.com/opinion/regents-of-the-university-of-minnesota-v-aga-medical-corp-mnd-2009.